Compare AbCellera Biologics Inc (ABCL) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs UiPath Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while UiPath Inc trades at $11.4 (market cap $6.04B). The key difference: UiPath Inc is far larger — about 2.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | PATH | |
|---|---|---|
Market Cap | $2.35B | $6.04B |
Sector | Health | Technology |
52-Week High | $8.12 | $19.29 |
52-Week Low | $2.78 | $9.38 |
Enterprise Value | $1.99B | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 2.29% on the day, with strong analyst support (82% buy ratings) and a $9.67 consensus price target suggesting 26% upside. The stock shows bullish technical momentum with moving averages supporting the trend, though RSI levels indicate potential overbought conditions. Recent positive developments include a major $876 million collaboration with Jazz Pharmaceuticals and board expansions, offsetting concerns about negative cash flow and profitability metrics.
While ABCL faces significant fundamental challenges with negative margins and cash burn, the company's strong cash position ($626M) and recent strategic partnerships provide runway for growth. The primary investment thesis hinges on successful pipeline development and platform monetization, with risks centered on execution and path to profitability. Wall Street remains optimistic about the long-term platform value despite near-term financial headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
